

January 2008
PROTOCOLS OPEN AT
FINGER LAKES HEMATOLOGY AND ONCOLOGY

BREAST:

ECOG-PACCT-1: Program for the Assessment of Clinical Cancer tests (PACCT-1):
Trial assigning individualized options for treatment: The
TAILORx Trial

*(*ER and/or PR +; 1.1 to 5.0 cm tumor; unfavorable features=intermediate or
poor nuclear and/or histologic grade, or lymphovascular
invasion.)*

E1503: A Double-Blind Phase III Trial of Doxorubicin and
Cyclophosphamide followed by Paclitaxel with Bevacizumab or
Placebo in Patients with Lymph Node Positive and High Risk
Lymph Node Negative Breast Cancer.

MA.27(CTSU) A Randomized phase III trial of Exemestane vs. Anastrozole in
post menopausal women with receptor positive primary breast
cancer. ******must be eligible for all three studies******

MA.27B(CTSU) The influence of five years of adjuvant Anastrozole or
Exemestane on bone mineral density in postmenopausal women
with primary breast cancer. (A companion study to
MA.27)******only osteo arm is open******

MA.27D(CTSU) The association of Breast Density changes, plasma hormone
changes, and breast cancer recurrence. (A companion study to
MA.27)

NSABP B.36 (CTSU) A clinical trial of adjuvant therapy comparing six cycles of 5-
fluorouracil, Epirubicin, and Cyclophosphamide (FEC) to four
cycle of Adriamycin and Cyclophosphamide (AC) in patients with
node-negative breast cancer.

S0221(CTSU) Phase III trial of continuous schedule of AC + G vs. Q2 week
schedule AC, followed by Paclitaxel given either every 2 weeks or
weekly for 12 weeks as post-operative adjuvant therapy in node-
positive or high-risk node negative breast cancer.

*(*stage I-III; tumor ≥ 2 cm and/or one or more axillary nodes +)*

January 2008
PROTOCOLS OPEN AT
FINGER LAKES HEMATOLOGY AND ONCOLOGY

- S0226 (CTSU) Phase III randomized trial of Anastrozole vs. Anastrozole and Fulvestrant as first line therapy for post menopausal women with metastatic breast cancer.
- S0230 Phase III Trial of LHRH Analog Administration during Chemotherapy to Reduce Ovarian Failure Following Standard Adjuvant Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer.
- E5103(CTSU) A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer.
- JMA.17R A double blind re-randomization to Letrozole or placebo for women completing five years of adjuvant Letrozole in the MA.17 study.

GASTROINTESTINAL:

- A4061020: A Randomized Phase II study of the Anti-Angiogenesis Agent (AG-013736) in combination with chemotherapy and Bevacizumab in patients with metastatic colorectal cancer preceded by a phase 1 portion. (A Pfizer sponsor study)

GENITOURINARY:

- S0421 A Phase III study of Docetaxel and Atrasentan vs. Docetaxel and placebo for patients with Advanced Hormone Refractory Prostate Cancer.
- S9346 Intermittent androgen deprivation in patients with stage D2 Prostate cancer, Phase III

LUNG:

- E1505 (CTSU) A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With completely Resected IB (≥ 4 cm) –IIIA Non-Small Cell Lung Cancer (NSCLC)

**January 2008
PROTOCOLS OPEN AT
FINGER LAKES HEMATOLOGY AND ONCOLOGY**

LYMPHOMA:

E4402 (CTSU)

Randomized phase III trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent Non-Hodgkin's lymphoma

LAB STUDIES:

S9925

Consent form for use of specimens for research.